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The thyroid hormone receptor 
β-selective agonist GC-1 
does not affect tolerance to 
exercise in hypothyroid rats
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ABSTRACT
Objective: Investigate the effect of GC-1 on tolerance to exercise in rats with experimental hypo-
thyroidism. Materials and methods: Hypothyroidism was induced with methimazole sodium and 
perchlorate treatment. Six groups with eight animals were studied: control group (C), hypothyroid 
group without treatment (HYPO); hypothyroidism treated with physiological doses of tetraiodothy-
ronine (T4) or 10 times higher (10×T4); hypothyroidism treated with equal molar doses of GC-1 (GC-1) 
or 10 times higher (10×GC-1).  After eight weeks, each animal underwent an exercise tolerance test 
by measuring the time (seconds), in which the rats were swimming with a load attached to their tails 
without being submerging for more than 10 sec. After the test, the animals were killed, and blood 
samples were collected for biochemical analysis, and the heart and soleus muscle were removed for 
weighing and morphometric analysis of the cardiomyocyte. Results: Hypothyroidism significantly 
reduced tolerance to exercise and, treatment with GC-1 1× or T4 in physiological doses recover toler-
ance test to normal parameters. However, high doses of T4 also decreased tolerance to physical ex-
ercise. Conversely, ten times higher doses of GC-1 did not impair tolerance to exercise. Interestingly, 
hypothyroidism, treated or not with T4 in a physiological range, GC-1 or even high doses of GC-1 
(10X) did not change cardiomyocyte diameters and relative weight of the soleus muscle. In contrast, 
higher doses of T4 significantly increased cardiomyocyte diameter and induced atrophy of the soleus 
muscle. Conclusion: Unlike T4, GC-1 in high doses did not modify tolerance to physical exercise in the 
rats with hypothyroidism. Arch Endocrinol Metab. 2015;59(2):141-7
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T hyroid hormones (THs) act on practically all hu-man organ systems, playing an important role 
in growth and development, and regulation of di-
verse homeostatic functions, including production of 
heat and energy. THs modulate myocardial function, 
metabolic rate, mineral bone density, lipid regulation, 
and cholesterol and lipoprotein metabolism (1-4). To 
initiate these effects, TH enter the target cell through 
a system mediated by transporters to bind to TH re-
ceptor [TR] located in the nucleus. These receptors 
are distributed in various tissues, and the affinity to 
TR is ten times greater for 3,5,3’-triiodothyronine 
(T3) than for 3,5,3′,5′-tetraiodothyronine (T4). The 
actions of THs are mediated by two different recep-
tors, namely receptor α (TRα) and receptor β (TRβ) 
(5). TRα and β are coded by two different genes lo-
cated on chromosomes 17 and 3, respectively. The 
isoforms α1, β1, β2, and β3, which result from the 
alternative splicing of messenger RNA or use of alter-
native promoters, are capable of binding to THs and 
are heterogeneously distributed in diverse tissues (6). 
TRβ1 is predominant in the kidney, brain, and liver, 
where it plays a role in the metabolism of blood cho-
lesterol and energy expenditure. TRβ2 is expressed 
only in the brain and anterior pituitary, where it regu-
lates the negative feedback mechanism of the TH in 
the hypothalamic-pituitary-thyroid axis. TRα1 is pre-
dominately expressed in the central nervous system, 
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cartilage, and bone (3-8). Given that T3 has a similar 
affinity to TRβ and TRα, even though the distribu-
tions of TRs differ, the administration of THs is re-
stricted for the treatment of hypothyroidism, as it can 
cause se rious adverse effects such as tachycardia and 
cardiac arrhythmias, which are associated with TRα 
stimulation in the heart (6-9).
However, as the TH increases energy expendi-
ture and significantly decreases the levels of choles-
terol and lipoproteins, several groups have tried to 
develop selective agonists of the β thyroid receptor, 
given that these ligands may help treat diseases such 
as obesity and dyslipidemia (10,11). Owing to their 
lower affinity to TRα1, selective agonists for TRβ 
do not cause, for example, tachycardia. Thus, va-
rious compounds with selective action for TRβ were 
synthesized, including [3,5-dimethyl-4-(4′-hydroxy-
3′-isopropylbenzyl)]-phenoxyacetic acid, known as 
GC-1 (12).
Studies have already shown that GC-1 effectively 
decreases obesity, increases metabolic rate and lipolysis, 
and decreases plasma levels of cholesterol, lipoproteins, 
and triglycerides without increasing cardiac frequency 
(13,14). In addition, unlike THs, the use of GC-1 does 
not induce osteoporosis or damage the skeletal tissue 
of rodents (15,16). Administrating GC-1 or GC-24, 
another TRβ-selective compound, to rats with hypo-
thyroidism did not affect muscle mass (16), genetic ex-
pression, or composition of muscle fibers (17).
Despite the positive effects of selective TRβ ago-
nists on metabolic rate and lipid profile already being 
well demonstrated in the literature, studies on cardiac 
side effects are more restricted to assessing the increase 
in cardiac frequency and/or presence of arrhythmias 
(13,14,18).
To date, no study has investigated the influence of 
selective TRβ1 agonists on tolerance to physical exer-
cise, despite that both hypothyroidism and hyperthy-
roidism are known to affect their role during exercise 
(19,20).
The aim of this study was to analyze the effect 
of GC-1 on tolerance to exercise in rats with experi-
mental hypothyroidism that were submitted to swim-
ming sessions. We assessed the tolerance to exercise 
in swimming sessions in hypothyroid rats treated 
with T4 and GC-1 in physiological and supraphysi-
ological doses. Our results revealed that GC-1, un-




This study was approved by the Animal Ethics Com-
mittee (CEUA) at the Institute of Biological Sciences at 
the University of Brasilia, Brasilia, Brazil (approval No. 
119158/2010). To implement the experimental pro-
tocol, adult Wistar rats from the bioterium of the Fed-
eral University of Uberlandia, Uberlandia, MG, Brazil 
weighing between 200 to 250 g were used. We selected 
48 animals, which were divided into six groups of eight 
animals as it follows: the euthyroid control group (C), 
hypothyroid group (HYPO), hypothyroid group treated 
with T4 (Sigma, Brazil) (T4) at a dose of 0.3 µg/100 g of 
body weight (BW) per day, treated with 10×T4 at a dose 
of 3 µg/100 g of BW per  day (group 10×T4), treated 
with GC-1 at a dose of 0.15 µg/100 g of BW per day 
(group GC-1), and treated with 10×GC-1 at a dose of 
1.5 µg/100 g of BW per day (group 10×GC-1). The 
GC-1 and 10×GC-1 groups were treated with equimolar 
doses of groups T4 and 10×T4. T4 was dissolved in 40 
mol/L NaOH, and GC-1 was dissolved in dimethyl sulf-
oxide at a concentration of 1 mg/mL. Then, both T4 and 
GC-1 were diluted in a saline solution. All the treatments 
were administered via daily intraperitoneal injections for a 
period of eight weeks. All the animals were weighed every 
three days to adjust the doses of the drugs when required.
Storing the animals
The animals were kept in cages in the bioterium at the 
Central University of Planalto de Araxa, MG, Brazil. 
The temperature, relative air humidity, and level of 
noise were kept constant throughout the experiment, 
with the light-dark cycle every 12 hours. All the animals 
received food and water ad libitum.
Induction of hypothyroidism
Hypothyroidism was induced by administering 0.1% 
methimazole plus 1% sodium perchlorate (MM 0.1% 
+ P 1%) in the drinking water of the rats during the 
experiment (21).
Effort test
Before the effort test was applied, the animals spent five 
days adapting to the aquatic environment. The swim-
ming apparatus for the effort test was a 20 × 50 cm tank, 
filled with water between 30ºC and 32ºC up to 40 cm, 
thereby preventing the rats from floating during the test.
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To verify the exercise tolerance, the following pro-
tocol was used as follows: each animal underwent a 
swimming session, with a load representing 5% of its 
BW attached to its tail, for as long as possible. This pro-
cedure guarantees an intensity of effort corresponding 
to the maximum stable phase of lactate. The test was 
validated when the rats were submerged for more than 
10 sec. Tolerance to effort was defined as the time that 
the animals spent swimming without being submerged 
for more than 10 sec (22).
Blood collection and analysis of hormone levels
After performed the effort tolerance test, the animals 
were euthanized by decapitation using a guillotine and 
blood samples were collected from the trunk. Each 
blood sample was centrifuged and immediately frozen. 
Subsequently, the total serum levels of T3, T4, and TSH 
were analyzed in the Clinical Analysis Laboratory of the 
Veterinary Hospital at the Federal University of Uber-
landia, using enzyme-linked immunosorbent assay. In-
tra and inter-assay coefficients of variation were respec-
tively: T3 = 9,6-10,3%, T4 = 4,3-4,5%, TSH = 4,6-7,6%.
Removal and weighing of the heart and soleus muscle
After being euthanized by decapitation, the thorax was 
opened, and the left posterior limb was dismembered 
to remove the heart and soleus muscle, respectively, 
which were then fixed in 10% formalin. After 24 hours, 
both the heart and soleus muscle were weighed using a 
Filizolla precision balance (0.001 g-Gehaka Ltda. Sao 
Paulo-Brazil). The relative weights of the cardiac and 
soleus muscles were determined by dividing the respec-
tive values obtained from the total weight of the animal 
on the day of euthanasia.
Afterward, the left ventricle was removed together 
with the interventricular septum to perform the histo-
logical sections. This procedure aims to verify possible 
hypertrophy or tissue degradation.
Histomorphometric analysis of the heart
The histological samples were prepared by immersing 
the material in paraffin, followed by hydration (depa-
raffinization) and finally dehydration of the material 
(diaphanization).
Next, two sections of the right ventricle were 
formed, and the smallest diameters of seven perpen-
dicularly cut cells were measured and identified in five 
different microscopic fields. The cell diameter was 
measured using scanned images taken using a binocular 
Olympus BX40 microscope at 40× resolution, coupled 
to an Olympus OLY-200 camera attached to a com-
puter via a Data Translation 3153 digital board. The 
measurements were performed using the software HL 
Image (Western Vision). The whole analysis was per-
formed using the double-blind technique. All the pro-
cedures to prepare the slides and equipment to analyze 
the material belonged to the Laboratory of Histology 
and Molecular Biology of the Institute of Biomedical 
Sciences at the Federal University of Uberlandia.
Statistical analysis
The data were statistically analyzed using the software 
Prism 4.0. One-way analysis of variance was used to 
verify any significant difference between the groups, 
followed by the Newman-Keuls test, with a significance 
level of 0.05.
RESULTS
Serum levels of T3, T4, and TSH
As shown in table 1, the serum levels of T3 and T4 were 
significantly lower, and that of TSH was significantly 
higher in the hypothyroid group than in the control 
group. Treatment with T4 in physiological doses normal-
ized the T3, T4, and TSH levels. Meanwhile, treatment 
with high doses of T4 (10×T4) significantly increased the 
serum T3 and T4 levels and decreased the TSH levels. 
The animals treated with GC-1 (GC-1 and 10×GC-1) 
had lower serum T3 and T4 levels than the control group. 
The serum TSH level was lower only for 10×GC-1. 
Table 1. Serum levels of thyroid hormones in the different groups
Groups/
Parameters T3 (ng/dL) T4 (ng/mL) TSH (µU/dL)
C 1.68 ± 0.25 46,58 ± 2.40 0.22 ± 0.01
HYPO 0.18 ± 0.07a 5.60 ± 0.50a 0.80 ± 0.03a
T4 1.30 ± 0.18b 49.65 ± 3.26b 0.18 ± 0.02b
10xT4 2.10 ± 0.07a,b,c 155.56 ± 5.78a,b,c 0.02 ± 0.0a,b,c
GC-1 0.3 ± 0.10a,c,d 4.29 ± 1.08a,c,d 0.16 ± 0.02b,d
10´GC-1 0.62 ± 0.16a,c,d 10.13 ± 1.06a,c,d 0.06 ± 0.02a,b,c,e
The values correspond to mean ± standard error. For each value, eight rats were used. T
3
 = 




 = Serum levels of T
4
; TSH = Serum levels of TSH; C = control group; 
HYPO = hypothyroid rats; T
4




 = hypothyroid rats 
treated with 10×T
4
; GC-1 = hypothyroid rats treated with GC-1; 10×GC-1 = hypothyroid rats 
treated with 10×GC-1. a = significant difference when compared to group C; b = significant 
difference when compared to group HYPO; c = significant difference when compared to group 
T4; d = significant difference when compared to group 10×T4; and e = significant difference 
when compared to group GC-1. p ≤ 0.05 in the Newman-Keuls test.
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Tolerance to the effort test
To address the response of each group to physical ef-
fort, the animals performed exercise in the form of 
swimming, with a load equivalent to 5% of their BW. 
As can be seen in figure 1, hypothyroidism decreased 
tolerance to physical exercise rather significantly. The 
control animals managed to swim for 426.75 ± 42.72 
sec, whereas the group with hypothyroidism tolerated 
only 110.13 ± 5.78 sec (p < 0.001). Treating the ani-
mals with T4 or GC-1 normalized tolerance to exercise 
(T4 = 414.63 ± 36.40 sec; GC-1 = 398.13 ± 21.71 
sec). However, when the animals were treated with 
higher doses of T4 (10×T4), tolerance to exercise also 
decreased quite significantly, reaching values similar to 
those in hypothyroidism (212 ± 22.57 sec; p < 0.001). 
Unlike T4, GC-1 at higher doses did not alter the toler-
ance of the animals to swimming (455.75 ± 25.58 sec).
Diameter of cardiomyocytes
Given that BW varies significantly when hypothyroidism 
or hyperthyroidism is present and that heart weight cor-
rected by BW may vary according to BW changes, we 
decided to analyze cardiomyocyte diameter in the dif-
ferent groups. As observed in figure 2, compared with 
the controls, the rats with hypothyroidism did not have 
altered cardiomyocyte diameters. Similarly, treatment 
with T4 and GC-1 in normal doses also did not cause 
such alteration. However, administering T4 in high dos-
es (group 10×T4) significantly increased cardiomyocyte 
diameter. On the other hand, high doses of GC-1 did 
not modify cardiomyocyte diameters (10×GC-1).
Figure 1. GC-1 did not alter tolerance to physical effort in the hypothyroid 
Wistar rats subjected to the swimming protocol, with a load equivalent to 
5% of body weight (n = 8 rats per group). Control (C); with untreated 
hypothyroidism (HYPO); with hypothyroidism treated with T4 in 
physiological doses (T4); high doses (10×T4); and with equimolar doses 
of GC-1 (GC-1 and 10×GC-1). The effort time was when the animals 
managed to swim without being submerged for more than 10 sec. a = 
















C HYPO T4 10xT4 GC1 10xGC1
Groups
Body parameters of the rats with experimentally 
induced hypothyroidism
Hypothyroidism caused a significant increase in BW 
and treatment with T4, GC-1 and 10×GC-1 normal-
ized these values (Table 2). However, using T4 at high 
doses (10×T4) caused a significant decrease in BW.
Hypothyroidism induced a significant increase in 
the weight of the heart when compared with the rest of 
the animals, whereas groups T4, 10×T4, and 10×GC-1 did 
not show different values to the control group. When 
analyzing the heart weight corrected by BW, a signifi-
cant increase was observed only for group 10×T4.
Figure 2. GC-1 did not alter cardiomyocyte diameter in the rats treated 
with physiological (GC-1) and high doses (10×GC-1; n = 8 rats per group). 
The diameter of the cardiomyocytes of the left ventricle was measured in 
the animals in the different groups. * Significant difference in group 

















C HYPO T4 10xT4 GC1 10xGC1
Groups
Table 2. Effect of treatment with T
4
 and GC-1 on the body parameters of 
the rats with experimentally induced hypothyroidism
Groups/
Parameters BW (g) HW (mg)
HW/BW 
(mg/g)
C 310.38 ± 10.67 970 ± 26.64 3.13 ± 0.09
HYPO 451.75 ± 15.17a 1572.5 ± 80.84a 3.48 ± 0.14
T4 337.50 ± 8.9b 1052.50 ± 30.62b 3.13 ± 0.11
10xT4 233.38 ± 15.22a,b,c 886.25 ± 34.57b,c 3.85 ± 0.2*
GC-1 341.38 ± 11.17b,d 1142.5 ± 26.98a,b,d 3.36 ± 0.09
10´GC-1 312.63 ± 18.07b,d 1020 ± 29.28b,d 3.32 ± 0.21
The values correspond to mean ± standard error. For each value, 8 rats were used. 
BW = body weight of the rats; HW = rat heart weight; HW/BW = relative weight of 
the rat heart. C = control group; HYPO = hypothyroid rats; T4 = hypothyroid rats 
treated with T4; 10×T4 = hypothyroid rats treated with 10×T4; GC-1 = hypothyroid 
rats treated with GC-1; 10×GC-1 = hypothyroid rats treated with 10×GC-1. a = 
significant difference when compared to C. b = significant difference when 
compared to HYPO. c = Significant difference when compared to T4. d = Significant 
difference when compared to 10×T4. * Significant difference when compared to 
the other groups.
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Relative weight of the soleus muscle
Next, to analyze the influence of the different treat-
ments on skeletal musculature, the relative weight of the 
soleus muscle was analyzed for each animal. As shown 
in figure 3, hypothyroidism did not alter the relative 
weight of the soleus muscle, nor did treatment with T4 
and GC-1 in physiological doses. Meanwhile, adminis-
tering T4 in high doses caused atrophy of the soleus 
muscle. Conversely, the administration of high doses of 
GC-1 (10×GC-1) did not affect soleus muscle mass.
hypothyroidism, decreases BW and cholesterol levels 
without causing tachycardia, arrhythmia, and osteopo-
rosis, or damaging the skeletal tissue of rodents (13-
16). Nevertheless, none of these studies evaluated the 
effect of GC-1, or even its analogue, GC-24, on tol-
erance to exercise in rats with experimentally induced 
hypothyroidism. Since exercise has been re commended 
to obesity and metabolic disease treatment, it is very 
important to investigate whether GC-1 can disrupt ex-
ercise capacity.  
Here, we investigated the effect of GC-1 on physi-
cal tolerance while the animals were in swimming ses-
sions. Our results show that unlike T4, physiological 
doses and high doses of GC-1 do not modify tolerance 
to physical exercise in rats with hypothyroidism.
The importance of THs upon tolerance to exercise 
has been long known, as patients with a hypo or hyper-
thyroidism display exercise intolerance (19,20).
Physiological studies on exercise show that toler-
ance to physical effort is a reflex of the combined action 
of respiratory, cardiovascular, and muscular systems. 
Therefore, disorders that alter one of these systems, 
as it is observed in hypo and/or hyperthyroidism, de-
crease performance during exercise (25).
In our study, we observed a significant decrease in 
tolerance in hypothyroid rats submitted to physical 
swimming exercise. This finding confirms previous re-
sults, which also observed a lower tolerance to exercise 
in rats with experimental hypothyroidism (26). The im-
portance of thyroid hormone in physical performance 
may be associated with the regulation of genetic expres-
sion of α and β myosin heavy chain in the myocardium 
by THs (27). Previous studies in rodents found that 
TH increases the expression of α myosin heavy chain 
(αMHC) and, decreases the expression of β myosin 
heavy chain (βMHC) (28). Therefore, hypothyroidism 
decreases αMHC expression, reduces cardiac contrac-
tility and impairs ejection fraction increment required 
during physical exercise (19). Thus, the downregula-
tion of αMHC (fast myosin with higher ATPase activ-
ity) and the upregulation of βMHC (slow myosin with 
low ATPase activity) (29) partially explain the decrease 
in cardiac contractility associated with hypothyroidism 
and, consequently, lower tolerance to swimming in the 
animals with hypothyroidism. 
Despite the direct effect on heart function, animals 
and patients studies have also shown that hypothyroid-
ism is associated with the reduction in blood flow to 
the skeletal musculature during physical effort (20,30). 
Figure 3. GC-1 did not cause atrophy of the soleus muscle in the rats 
treated with both physiological (GC-1) and high doses (10×GC-1; n = 8 
rats per group). The diameter of the cardiomyocytes of the left ventricle 
was measured in the animals in the different groups. * Significant 























C HYPO T4 10xT4 GC1 10xGC1
Groups
DISCUSSION
With a growing and aging world population, we have 
observed over the past decade a significant increase in 
the prevalence of obesity and diabetes and, consequent-
ly, in their comorbidities, which will continue to do so 
in the future. The prevalence of obesity in the world 
population increased from 6.4% in 1980 to 12% in 
2008 (23), and the prevalence of diabetes in the adult 
population will increase from 6.4% in 2010 to 7.7% in 
2030 (24). Diverse strategies can be applied to tackle 
these problems, including pharmacological and non-
pharmacological methods such as lifestyle changes, in-
cluding regular exercise. Among the pharmacological 
approach, a therapeutic option that has been investigat-
ed is the development of selective agonists for the thy-
roid receptor beta. These ligands have been suggested 
to help control obesity and hypercholesterolemia with-
out the side effects caused by TH in the heart, bone 
and skeletal muscle (13-17). One of these compounds 
is GC-1, which when administered to animals with 
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Similarly to our hypothyroid animals, the treat-
ment with high doses of T4 (10×T4), but not GC-1, 
also diminished tolerance to swimming effort test 
(Figure 1). Additionally, animals with hyperthyroid-
ism (10×T4 – Figure 2) exhibited increased cardio-
myocyte diameter and ventricular hypertrophy. Pro-
longed exposure to high concentrations of TH causes 
an increase in the myocardium work rate due to 
blood-volume overload, with inefficient use of energy 
by the myocardium. Consequently, hypertrophy of the 
cardiomyocytes is not accompanied by increased effi-
ciency of the cardiac pump since it impairs tolerance 
to physical exercise (31). The decreased tolerance to 
exercise with hyperthyroidism may also be related to 
dysfunction of the skeletal muscle due to the reduced 
expression of oxidative and glycolytic enzymes (32). 
Although we did not assess the genetic expression or 
protein and biochemical content of the skeletal muscle 
in our study, the animals treated with supraphysiologi-
cal doses of T4, but not GC-1, presented an atrophy of 
the soleus muscle. 
Previous studies already showed that supraphysi-
ological doses of GC-1 increase energy expenditure 
without causing tissue damage or altering heart mass 
(33). GC-1 has no adverse effects on the myocardium 
and skeletal muscle because TRα1 is predominantly ex-
pressed in these tissues (1) and owing to the pharmaco-
kinetic distribution of GC-1 that predominates in other 
tissues such as liver (34). Collectively, these findings 
suggest that GC-1 combined with exercise may be safe 
to treat hypercholesterolemia and or obesity.
In conclusion, our results show that GC-1 adminis-
tered in physiological and supraphysiological doses 
does not alter effort tolerance test nor does it modify 
the diameter of cardiomyocytes. Therefore, GC-1 and 
perhaps other selective β thyroid agonists may be used 
alongside regular physical exercise, the fundamental 
strategy for the treatment of obesity and other meta-
bolic diseases.
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The thyroid hormone receptor 
β-selective agonist GC-1 
does not affect tolerance to 
exercise in hypothyroid rats
Alexandre Gonçalves1, Chineyder Corrêa Tolentino2,  
Fernanda Rodrigues de Souza3, Juliana Carla da Costa Huss4, 
Karolinne de Lourdes Zinato5, Leandro Teixeira Paranhos Lopes3, 
Roberto Furlanetto Júnior6, Francisco de Assis Rocha Neves7
ABSTRACT
Objective: Investigate the effect of GC-1 on tolerance to exercise in rats with experimental hypo-
thyroidism. Materials and methods: Hypothyroidism was induced with methimazole sodium and 
perchlorate treatment. Six groups with eight animals were studied: control group (C), hypothyroid 
group without treatment (HYPO); hypothyroidism treated with physiological doses of tetraiodothy-
ronine (T4) or 10 times higher (10×T4); hypothyroidism treated with equal molar doses of GC-1 (GC-1) 
or 10 times higher (10×GC-1).  After eight weeks, each animal underwent an exercise tolerance test 
by measuring the time (seconds), in which the rats were swimming with a load attached to their tails 
without being submerging for more than 10 sec. After the test, the animals were killed, and blood 
samples were collected for biochemical analysis, and the heart and soleus muscle were removed for 
weighing and morphometric analysis of the cardiomyocyte. Results: Hypothyroidism significantly 
reduced tolerance to exercise and, treatment with GC-1 1× or T4 in physiological doses recover toler-
ance test to normal parameters. However, high doses of T4 also decreased tolerance to physical ex-
ercise. Conversely, ten times higher doses of GC-1 did not impair tolerance to exercise. Interestingly, 
hypothyroidism, treated or not with T4 in a physiological range, GC-1 or even high doses of GC-1 
(10X) did not change cardiomyocyte diameters and relative weight of the soleus muscle. In contrast, 
higher doses of T4 significantly increased cardiomyocyte diameter and induced atrophy of the soleus 
muscle. Conclusion: Unlike T4, GC-1 in high doses did not modify tolerance to physical exercise in the 
rats with hypothyroidism. Arch Endocrinol Metab. 2015;59(2):141-7
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T hyroid hormones (THs) act on practically all hu-man organ systems, playing an important role 
in growth and development, and regulation of di-
verse homeostatic functions, including production of 
heat and energy. THs modulate myocardial function, 
metabolic rate, mineral bone density, lipid regulation, 
and cholesterol and lipoprotein metabolism (1-4). To 
initiate these effects, TH enter the target cell through 
a system mediated by transporters to bind to TH re-
ceptor [TR] located in the nucleus. These receptors 
are distributed in various tissues, and the affinity to 
TR is ten times greater for 3,5,3’-triiodothyronine 
(T3) than for 3,5,3′,5′-tetraiodothyronine (T4). The 
actions of THs are mediated by two different recep-
tors, namely receptor α (TRα) and receptor β (TRβ) 
(5). TRα and β are coded by two different genes lo-
cated on chromosomes 17 and 3, respectively. The 
isoforms α1, β1, β2, and β3, which result from the 
alternative splicing of messenger RNA or use of alter-
native promoters, are capable of binding to THs and 
are heterogeneously distributed in diverse tissues (6). 
TRβ1 is predominant in the kidney, brain, and liver, 
where it plays a role in the metabolism of blood cho-
lesterol and energy expenditure. TRβ2 is expressed 
only in the brain and anterior pituitary, where it regu-
lates the negative feedback mechanism of the TH in 
the hypothalamic-pituitary-thyroid axis. TRα1 is pre-
dominately expressed in the central nervous system, 
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cartilage, and bone (3-8). Given that T3 has a similar 
affinity to TRβ and TRα, even though the distribu-
tions of TRs differ, the administration of THs is re-
stricted for the treatment of hypothyroidism, as it can 
cause se rious adverse effects such as tachycardia and 
cardiac arrhythmias, which are associated with TRα 
stimulation in the heart (6-9).
However, as the TH increases energy expendi-
ture and significantly decreases the levels of choles-
terol and lipoproteins, several groups have tried to 
develop selective agonists of the β thyroid receptor, 
given that these ligands may help treat diseases such 
as obesity and dyslipidemia (10,11). Owing to their 
lower affinity to TRα1, selective agonists for TRβ 
do not cause, for example, tachycardia. Thus, va-
rious compounds with selective action for TRβ were 
synthesized, including [3,5-dimethyl-4-(4′-hydroxy-
3′-isopropylbenzyl)]-phenoxyacetic acid, known as 
GC-1 (12).
Studies have already shown that GC-1 effectively 
decreases obesity, increases metabolic rate and lipolysis, 
and decreases plasma levels of cholesterol, lipoproteins, 
and triglycerides without increasing cardiac frequency 
(13,14). In addition, unlike THs, the use of GC-1 does 
not induce osteoporosis or damage the skeletal tissue 
of rodents (15,16). Administrating GC-1 or GC-24, 
another TRβ-selective compound, to rats with hypo-
thyroidism did not affect muscle mass (16), genetic ex-
pression, or composition of muscle fibers (17).
Despite the positive effects of selective TRβ ago-
nists on metabolic rate and lipid profile already being 
well demonstrated in the literature, studies on cardiac 
side effects are more restricted to assessing the increase 
in cardiac frequency and/or presence of arrhythmias 
(13,14,18).
To date, no study has investigated the influence of 
selective TRβ1 agonists on tolerance to physical exer-
cise, despite that both hypothyroidism and hyperthy-
roidism are known to affect their role during exercise 
(19,20).
The aim of this study was to analyze the effect 
of GC-1 on tolerance to exercise in rats with experi-
mental hypothyroidism that were submitted to swim-
ming sessions. We assessed the tolerance to exercise 
in swimming sessions in hypothyroid rats treated 
with T4 and GC-1 in physiological and supraphysi-
ological doses. Our results revealed that GC-1, un-




This study was approved by the Animal Ethics Com-
mittee (CEUA) at the Institute of Biological Sciences at 
the University of Brasilia, Brasilia, Brazil (approval No. 
119158/2010). To implement the experimental pro-
tocol, adult Wistar rats from the bioterium of the Fed-
eral University of Uberlandia, Uberlandia, MG, Brazil 
weighing between 200 to 250 g were used. We selected 
48 animals, which were divided into six groups of eight 
animals as it follows: the euthyroid control group (C), 
hypothyroid group (HYPO), hypothyroid group treated 
with T4 (Sigma, Brazil) (T4) at a dose of 0.3 µg/100 g of 
body weight (BW) per day, treated with 10×T4 at a dose 
of 3 µg/100 g of BW per  day (group 10×T4), treated 
with GC-1 at a dose of 0.15 µg/100 g of BW per day 
(group GC-1), and treated with 10×GC-1 at a dose of 
1.5 µg/100 g of BW per day (group 10×GC-1). The 
GC-1 and 10×GC-1 groups were treated with equimolar 
doses of groups T4 and 10×T4. T4 was dissolved in 40 
mol/L NaOH, and GC-1 was dissolved in dimethyl sulf-
oxide at a concentration of 1 mg/mL. Then, both T4 and 
GC-1 were diluted in a saline solution. All the treatments 
were administered via daily intraperitoneal injections for a 
period of eight weeks. All the animals were weighed every 
three days to adjust the doses of the drugs when required.
Storing the animals
The animals were kept in cages in the bioterium at the 
Central University of Planalto de Araxa, MG, Brazil. 
The temperature, relative air humidity, and level of 
noise were kept constant throughout the experiment, 
with the light-dark cycle every 12 hours. All the animals 
received food and water ad libitum.
Induction of hypothyroidism
Hypothyroidism was induced by administering 0.1% 
methimazole plus 1% sodium perchlorate (MM 0.1% 
+ P 1%) in the drinking water of the rats during the 
experiment (21).
Effort test
Before the effort test was applied, the animals spent five 
days adapting to the aquatic environment. The swim-
ming apparatus for the effort test was a 20 × 50 cm tank, 
filled with water between 30ºC and 32ºC up to 40 cm, 
thereby preventing the rats from floating during the test.


















143Arch Endocrinol Metab. 2015;59/2
To verify the exercise tolerance, the following pro-
tocol was used as follows: each animal underwent a 
swimming session, with a load representing 5% of its 
BW attached to its tail, for as long as possible. This pro-
cedure guarantees an intensity of effort corresponding 
to the maximum stable phase of lactate. The test was 
validated when the rats were submerged for more than 
10 sec. Tolerance to effort was defined as the time that 
the animals spent swimming without being submerged 
for more than 10 sec (22).
Blood collection and analysis of hormone levels
After performed the effort tolerance test, the animals 
were euthanized by decapitation using a guillotine and 
blood samples were collected from the trunk. Each 
blood sample was centrifuged and immediately frozen. 
Subsequently, the total serum levels of T3, T4, and TSH 
were analyzed in the Clinical Analysis Laboratory of the 
Veterinary Hospital at the Federal University of Uber-
landia, using enzyme-linked immunosorbent assay. In-
tra and inter-assay coefficients of variation were respec-
tively: T3 = 9,6-10,3%, T4 = 4,3-4,5%, TSH = 4,6-7,6%.
Removal and weighing of the heart and soleus muscle
After being euthanized by decapitation, the thorax was 
opened, and the left posterior limb was dismembered 
to remove the heart and soleus muscle, respectively, 
which were then fixed in 10% formalin. After 24 hours, 
both the heart and soleus muscle were weighed using a 
Filizolla precision balance (0.001 g-Gehaka Ltda. Sao 
Paulo-Brazil). The relative weights of the cardiac and 
soleus muscles were determined by dividing the respec-
tive values obtained from the total weight of the animal 
on the day of euthanasia.
Afterward, the left ventricle was removed together 
with the interventricular septum to perform the histo-
logical sections. This procedure aims to verify possible 
hypertrophy or tissue degradation.
Histomorphometric analysis of the heart
The histological samples were prepared by immersing 
the material in paraffin, followed by hydration (depa-
raffinization) and finally dehydration of the material 
(diaphanization).
Next, two sections of the right ventricle were 
formed, and the smallest diameters of seven perpen-
dicularly cut cells were measured and identified in five 
different microscopic fields. The cell diameter was 
measured using scanned images taken using a binocular 
Olympus BX40 microscope at 40× resolution, coupled 
to an Olympus OLY-200 camera attached to a com-
puter via a Data Translation 3153 digital board. The 
measurements were performed using the software HL 
Image (Western Vision). The whole analysis was per-
formed using the double-blind technique. All the pro-
cedures to prepare the slides and equipment to analyze 
the material belonged to the Laboratory of Histology 
and Molecular Biology of the Institute of Biomedical 
Sciences at the Federal University of Uberlandia.
Statistical analysis
The data were statistically analyzed using the software 
Prism 4.0. One-way analysis of variance was used to 
verify any significant difference between the groups, 
followed by the Newman-Keuls test, with a significance 
level of 0.05.
RESULTS
Serum levels of T3, T4, and TSH
As shown in table 1, the serum levels of T3 and T4 were 
significantly lower, and that of TSH was significantly 
higher in the hypothyroid group than in the control 
group. Treatment with T4 in physiological doses normal-
ized the T3, T4, and TSH levels. Meanwhile, treatment 
with high doses of T4 (10×T4) significantly increased the 
serum T3 and T4 levels and decreased the TSH levels. 
The animals treated with GC-1 (GC-1 and 10×GC-1) 
had lower serum T3 and T4 levels than the control group. 
The serum TSH level was lower only for 10×GC-1. 
Table 1. Serum levels of thyroid hormones in the different groups
Groups/
Parameters T3 (ng/dL) T4 (ng/mL) TSH (µU/dL)
C 1.68 ± 0.25 46,58 ± 2.40 0.22 ± 0.01
HYPO 0.18 ± 0.07a 5.60 ± 0.50a 0.80 ± 0.03a
T4 1.30 ± 0.18b 49.65 ± 3.26b 0.18 ± 0.02b
10xT4 2.10 ± 0.07a,b,c 155.56 ± 5.78a,b,c 0.02 ± 0.0a,b,c
GC-1 0.3 ± 0.10a,c,d 4.29 ± 1.08a,c,d 0.16 ± 0.02b,d
10´GC-1 0.62 ± 0.16a,c,d 10.13 ± 1.06a,c,d 0.06 ± 0.02a,b,c,e
The values correspond to mean ± standard error. For each value, eight rats were used. T
3
 = 




 = Serum levels of T
4
; TSH = Serum levels of TSH; C = control group; 
HYPO = hypothyroid rats; T
4




 = hypothyroid rats 
treated with 10×T
4
; GC-1 = hypothyroid rats treated with GC-1; 10×GC-1 = hypothyroid rats 
treated with 10×GC-1. a = significant difference when compared to group C; b = significant 
difference when compared to group HYPO; c = significant difference when compared to group 
T4; d = significant difference when compared to group 10×T4; and e = significant difference 
when compared to group GC-1. p ≤ 0.05 in the Newman-Keuls test.
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Tolerance to the effort test
To address the response of each group to physical ef-
fort, the animals performed exercise in the form of 
swimming, with a load equivalent to 5% of their BW. 
As can be seen in figure 1, hypothyroidism decreased 
tolerance to physical exercise rather significantly. The 
control animals managed to swim for 426.75 ± 42.72 
sec, whereas the group with hypothyroidism tolerated 
only 110.13 ± 5.78 sec (p < 0.001). Treating the ani-
mals with T4 or GC-1 normalized tolerance to exercise 
(T4 = 414.63 ± 36.40 sec; GC-1 = 398.13 ± 21.71 
sec). However, when the animals were treated with 
higher doses of T4 (10×T4), tolerance to exercise also 
decreased quite significantly, reaching values similar to 
those in hypothyroidism (212 ± 22.57 sec; p < 0.001). 
Unlike T4, GC-1 at higher doses did not alter the toler-
ance of the animals to swimming (455.75 ± 25.58 sec).
Diameter of cardiomyocytes
Given that BW varies significantly when hypothyroidism 
or hyperthyroidism is present and that heart weight cor-
rected by BW may vary according to BW changes, we 
decided to analyze cardiomyocyte diameter in the dif-
ferent groups. As observed in figure 2, compared with 
the controls, the rats with hypothyroidism did not have 
altered cardiomyocyte diameters. Similarly, treatment 
with T4 and GC-1 in normal doses also did not cause 
such alteration. However, administering T4 in high dos-
es (group 10×T4) significantly increased cardiomyocyte 
diameter. On the other hand, high doses of GC-1 did 
not modify cardiomyocyte diameters (10×GC-1).
Figure 1. GC-1 did not alter tolerance to physical effort in the hypothyroid 
Wistar rats subjected to the swimming protocol, with a load equivalent to 
5% of body weight (n = 8 rats per group). Control (C); with untreated 
hypothyroidism (HYPO); with hypothyroidism treated with T4 in 
physiological doses (T4); high doses (10×T4); and with equimolar doses 
of GC-1 (GC-1 and 10×GC-1). The effort time was when the animals 
managed to swim without being submerged for more than 10 sec. a = 
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Body parameters of the rats with experimentally 
induced hypothyroidism
Hypothyroidism caused a significant increase in BW 
and treatment with T4, GC-1 and 10×GC-1 normal-
ized these values (Table 2). However, using T4 at high 
doses (10×T4) caused a significant decrease in BW.
Hypothyroidism induced a significant increase in 
the weight of the heart when compared with the rest of 
the animals, whereas groups T4, 10×T4, and 10×GC-1 did 
not show different values to the control group. When 
analyzing the heart weight corrected by BW, a signifi-
cant increase was observed only for group 10×T4.
Figure 2. GC-1 did not alter cardiomyocyte diameter in the rats treated 
with physiological (GC-1) and high doses (10×GC-1; n = 8 rats per group). 
The diameter of the cardiomyocytes of the left ventricle was measured in 
the animals in the different groups. * Significant difference in group 
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Table 2. Effect of treatment with T
4
 and GC-1 on the body parameters of 
the rats with experimentally induced hypothyroidism
Groups/
Parameters BW (g) HW (mg)
HW/BW 
(mg/g)
C 310.38 ± 10.67 970 ± 26.64 3.13 ± 0.09
HYPO 451.75 ± 15.17a 1572.5 ± 80.84a 3.48 ± 0.14
T4 337.50 ± 8.9b 1052.50 ± 30.62b 3.13 ± 0.11
10xT4 233.38 ± 15.22a,b,c 886.25 ± 34.57b,c 3.85 ± 0.2*
GC-1 341.38 ± 11.17b,d 1142.5 ± 26.98a,b,d 3.36 ± 0.09
10´GC-1 312.63 ± 18.07b,d 1020 ± 29.28b,d 3.32 ± 0.21
The values correspond to mean ± standard error. For each value, 8 rats were used. 
BW = body weight of the rats; HW = rat heart weight; HW/BW = relative weight of 
the rat heart. C = control group; HYPO = hypothyroid rats; T4 = hypothyroid rats 
treated with T4; 10×T4 = hypothyroid rats treated with 10×T4; GC-1 = hypothyroid 
rats treated with GC-1; 10×GC-1 = hypothyroid rats treated with 10×GC-1. a = 
significant difference when compared to C. b = significant difference when 
compared to HYPO. c = Significant difference when compared to T4. d = Significant 
difference when compared to 10×T4. * Significant difference when compared to 
the other groups.
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Relative weight of the soleus muscle
Next, to analyze the influence of the different treat-
ments on skeletal musculature, the relative weight of the 
soleus muscle was analyzed for each animal. As shown 
in figure 3, hypothyroidism did not alter the relative 
weight of the soleus muscle, nor did treatment with T4 
and GC-1 in physiological doses. Meanwhile, adminis-
tering T4 in high doses caused atrophy of the soleus 
muscle. Conversely, the administration of high doses of 
GC-1 (10×GC-1) did not affect soleus muscle mass.
hypothyroidism, decreases BW and cholesterol levels 
without causing tachycardia, arrhythmia, and osteopo-
rosis, or damaging the skeletal tissue of rodents (13-
16). Nevertheless, none of these studies evaluated the 
effect of GC-1, or even its analogue, GC-24, on tol-
erance to exercise in rats with experimentally induced 
hypothyroidism. Since exercise has been re commended 
to obesity and metabolic disease treatment, it is very 
important to investigate whether GC-1 can disrupt ex-
ercise capacity.  
Here, we investigated the effect of GC-1 on physi-
cal tolerance while the animals were in swimming ses-
sions. Our results show that unlike T4, physiological 
doses and high doses of GC-1 do not modify tolerance 
to physical exercise in rats with hypothyroidism.
The importance of THs upon tolerance to exercise 
has been long known, as patients with a hypo or hyper-
thyroidism display exercise intolerance (19,20).
Physiological studies on exercise show that toler-
ance to physical effort is a reflex of the combined action 
of respiratory, cardiovascular, and muscular systems. 
Therefore, disorders that alter one of these systems, 
as it is observed in hypo and/or hyperthyroidism, de-
crease performance during exercise (25).
In our study, we observed a significant decrease in 
tolerance in hypothyroid rats submitted to physical 
swimming exercise. This finding confirms previous re-
sults, which also observed a lower tolerance to exercise 
in rats with experimental hypothyroidism (26). The im-
portance of thyroid hormone in physical performance 
may be associated with the regulation of genetic expres-
sion of α and β myosin heavy chain in the myocardium 
by THs (27). Previous studies in rodents found that 
TH increases the expression of α myosin heavy chain 
(αMHC) and, decreases the expression of β myosin 
heavy chain (βMHC) (28). Therefore, hypothyroidism 
decreases αMHC expression, reduces cardiac contrac-
tility and impairs ejection fraction increment required 
during physical exercise (19). Thus, the downregula-
tion of αMHC (fast myosin with higher ATPase activ-
ity) and the upregulation of βMHC (slow myosin with 
low ATPase activity) (29) partially explain the decrease 
in cardiac contractility associated with hypothyroidism 
and, consequently, lower tolerance to swimming in the 
animals with hypothyroidism. 
Despite the direct effect on heart function, animals 
and patients studies have also shown that hypothyroid-
ism is associated with the reduction in blood flow to 
the skeletal musculature during physical effort (20,30). 
Figure 3. GC-1 did not cause atrophy of the soleus muscle in the rats 
treated with both physiological (GC-1) and high doses (10×GC-1; n = 8 
rats per group). The diameter of the cardiomyocytes of the left ventricle 
was measured in the animals in the different groups. * Significant 
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DISCUSSION
With a growing and aging world population, we have 
observed over the past decade a significant increase in 
the prevalence of obesity and diabetes and, consequent-
ly, in their comorbidities, which will continue to do so 
in the future. The prevalence of obesity in the world 
population increased from 6.4% in 1980 to 12% in 
2008 (23), and the prevalence of diabetes in the adult 
population will increase from 6.4% in 2010 to 7.7% in 
2030 (24). Diverse strategies can be applied to tackle 
these problems, including pharmacological and non-
pharmacological methods such as lifestyle changes, in-
cluding regular exercise. Among the pharmacological 
approach, a therapeutic option that has been investigat-
ed is the development of selective agonists for the thy-
roid receptor beta. These ligands have been suggested 
to help control obesity and hypercholesterolemia with-
out the side effects caused by TH in the heart, bone 
and skeletal muscle (13-17). One of these compounds 
is GC-1, which when administered to animals with 
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Similarly to our hypothyroid animals, the treat-
ment with high doses of T4 (10×T4), but not GC-1, 
also diminished tolerance to swimming effort test 
(Figure 1). Additionally, animals with hyperthyroid-
ism (10×T4 – Figure 2) exhibited increased cardio-
myocyte diameter and ventricular hypertrophy. Pro-
longed exposure to high concentrations of TH causes 
an increase in the myocardium work rate due to 
blood-volume overload, with inefficient use of energy 
by the myocardium. Consequently, hypertrophy of the 
cardiomyocytes is not accompanied by increased effi-
ciency of the cardiac pump since it impairs tolerance 
to physical exercise (31). The decreased tolerance to 
exercise with hyperthyroidism may also be related to 
dysfunction of the skeletal muscle due to the reduced 
expression of oxidative and glycolytic enzymes (32). 
Although we did not assess the genetic expression or 
protein and biochemical content of the skeletal muscle 
in our study, the animals treated with supraphysiologi-
cal doses of T4, but not GC-1, presented an atrophy of 
the soleus muscle. 
Previous studies already showed that supraphysi-
ological doses of GC-1 increase energy expenditure 
without causing tissue damage or altering heart mass 
(33). GC-1 has no adverse effects on the myocardium 
and skeletal muscle because TRα1 is predominantly ex-
pressed in these tissues (1) and owing to the pharmaco-
kinetic distribution of GC-1 that predominates in other 
tissues such as liver (34). Collectively, these findings 
suggest that GC-1 combined with exercise may be safe 
to treat hypercholesterolemia and or obesity.
In conclusion, our results show that GC-1 adminis-
tered in physiological and supraphysiological doses 
does not alter effort tolerance test nor does it modify 
the diameter of cardiomyocytes. Therefore, GC-1 and 
perhaps other selective β thyroid agonists may be used 
alongside regular physical exercise, the fundamental 
strategy for the treatment of obesity and other meta-
bolic diseases.
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